Literature DB >> 8960729

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

L Truyen1, J H van Waesberghe, M A van Walderveen, B W van Oosten, C H Polman, O R Hommes, H J Adèr, F Barkhof.   

Abstract

MRI findings are increasingly used as outcome measures in therapeutic trials in MS. The discrepancy between the extent of the lesions on conventional T2 images and the clinical condition of the patient is one of the problems encountered in such studies. This clinical-radiological paradox prevents the use of MRI data as surrogate markers of disability in MS. A recent pilot study suggested a relationship between hypointense lesions on T1 MRI and disability. To assess in more detail the correlation of changes in hypointense lesion load on T1-weighted spin-echo MR images ("black holes") with changes in disability in MS, we studied 46 patients with clinically definite MS at baseline and after a median follow-up of 40 months. There was a significant correlation between baseline disability and hypointense lesion load (Spearman rank correlation coefficient [SRCC] = 0.46, p = 0.001). In secondary progressive patients, the rate of accumulation of these "black holes" was significantly related to progression rate (SRCC = 0.81, p < 0.0001). We speculate that the appearance of hypointense lesions is the MRI equivalent of a failure of remission. Overall, T1 lesion load measurements correlated better with clinical assessments than T2 lesion load measurements. Quantification of hypointense lesion load on T1-weighted spin-echo MRI helps to resolve the clinical-radiological paradox between disability and MRI and has the potential to be a surrogate marker of disability in MS.

Entities:  

Mesh:

Year:  1996        PMID: 8960729     DOI: 10.1212/wnl.47.6.1469

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  90 in total

1.  Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis.

Authors:  J A Koziol; S Wagner; D F Sobel; L S Slivka; J S Romine; J C Sipe; H P Adams
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

Review 2.  Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials.

Authors:  Frederik Barkhof
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  Absence of perforin expression confers axonal protection despite demyelination.

Authors:  Charles L Howe; Jaimie D Adelson; Moses Rodriguez
Journal:  Neurobiol Dis       Date:  2006-11-16       Impact factor: 5.996

4.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

5.  Segmentation and quantification of black holes in multiple sclerosis.

Authors:  Sushmita Datta; Balasrinivasa Rao Sajja; Renjie He; Jerry S Wolinsky; Rakesh K Gupta; Ponnada A Narayana
Journal:  Neuroimage       Date:  2005-08-26       Impact factor: 6.556

Review 6.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 7.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

8.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

Review 9.  Neuroimaging in multiple sclerosis: neurotherapeutic implications.

Authors:  Nancy L Sicotte
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

10.  Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.

Authors:  Belinda S Y Li; Juleiga Regal; Brian J Soher; Lois J Mannon; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.